KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) Gross Margin (2020 - 2025)

AbCellera Biologics filings provide 6 years of Gross Margin readings, the most recent being 67.55% for Q3 2025.

  • Quarterly Gross Margin rose 1573.0% to 67.55% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 102.49% through Sep 2025, down 190.0% year-over-year, with the annual reading at 100.0% for FY2024, 0.0% changed from the prior year.
  • Gross Margin hit 67.55% in Q3 2025 for AbCellera Biologics, down from 82.39% in the prior quarter.
  • Across five years, Gross Margin topped out at 348.92% in Q4 2022 and bottomed at 32.89% in Q1 2025.
  • Average Gross Margin over 5 years is 107.31%, with a median of 82.39% recorded in 2025.
  • The largest annual shift saw Gross Margin soared 25023bps in 2022 before it crashed -12821bps in 2023.
  • AbCellera Biologics' Gross Margin stood at 98.69% in 2021, then surged by 254bps to 348.92% in 2022, then crashed by -37bps to 220.71% in 2023, then surged by 32bps to 290.79% in 2024, then crashed by -77bps to 67.55% in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Gross Margin are 67.55% (Q3 2025), 82.39% (Q2 2025), and 32.89% (Q1 2025).